Deutsche Bank Ag\ Protagonist Therapeutics, Inc Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Deutsche Bank Ag\ holds 120,169 shares of PTGX stock, worth $4.94 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

120,169

Previous 908,348 86.77%

Holding current value

$4.94 Million

Previous $31.5 Million 82.84%

% of portfolio

0.0%

Previous 0.01%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$33.72 - $47.33 $26.6 Million - $37.3 Million	-788,179 Reduced 86.77%	120,169 $5.4 Million
Q2 2024 Aug 14, 2024	SELL	$24.66 - $34.8 $60,614 - $85,538	-2,458 Reduced 0.27%	908,348 $31.5 Million
Q1 2024 May 15, 2024	BUY	$21.79 - $32.15 $17,301 - $25,527	794 Added 0.09%	910,806 $26.3 Million
Q4 2023 Feb 14, 2024	BUY	$14.05 - $23.44 $11.8 Million - $19.6 Million	838,099 Added 1165.43%	910,012 $20.9 Million
Q3 2023 Nov 09, 2023	SELL	$16.68 - $23.66 $13.2 Million - $18.7 Million	-789,411 Reduced 91.65%	71,913 $1.2 Million
Q2 2023 Aug 14, 2023	SELL	$18.02 - $29.36 $1.76 Million - $2.86 Million	-97,567 Reduced 10.17%	861,324 $23.8 Million
Q1 2023 May 15, 2023	BUY	$10.78 - $25.38 $358,208 - $843,352	33,229 Added 3.59%	958,891 $22.1 Million
Q4 2022 Feb 13, 2023	BUY	$7.36 - $11.17 $833,939 - $1.27 Million	113,307 Added 13.95%	925,662 $10.1 Million
Q3 2022 Nov 14, 2022	SELL	$7.86 - $11.71 $43,049 - $64,135	-5,477 Reduced 0.67%	812,355 $6.85 Million
Q2 2022 Aug 11, 2022	SELL	$7.06 - $25.52 $31,706 - $114,610	-4,491 Reduced 0.55%	817,832 $6.47 Million
Q1 2022 May 13, 2022	SELL	$23.34 - $36.08 $59,493 - $91,967	-2,549 Reduced 0.31%	822,323 $19.5 Million
Q4 2021 Feb 11, 2022	BUY	$17.63 - $37.1 $27,890 - $58,692	1,582 Added 0.19%	824,872 $28.2 Million
Q3 2021 Nov 04, 2021	BUY	$12.95 - $49.69 $20,305 - $77,913	1,568 Added 0.19%	823,290 $14.6 Million
Q2 2021 Aug 11, 2021	BUY	$25.57 - $44.88 $20.4 Million - $35.7 Million	796,161 Added 3114.75%	821,722 $36.9 Million
Q1 2021 May 13, 2021	BUY	$19.02 - $31.15 $7,588 - $12,428	399 Added 1.59%	25,561 $662,000
Q4 2020 Feb 16, 2021	BUY	$18.49 - $25.13 $162,508 - $220,867	8,789 Added 53.68%	25,162 $507,000
Q3 2020 Nov 12, 2020	BUY	$15.19 - $22.4 $73,139 - $107,856	4,815 Added 41.66%	16,373 $320,000
Q2 2020 Aug 13, 2020	BUY	$6.19 - $18.84 $33,673 - $102,489	5,440 Added 88.92%	11,558 $205,000
Q1 2020 May 14, 2020	SELL	$5.4 - $9.22 $119,410 - $203,881	-22,113 Reduced 78.33%	6,118 $43,000
Q4 2019 Feb 14, 2020	BUY	$4.69 - $13.45 $37,590 - $107,801	8,015 Added 39.65%	28,231 $197,000
Q3 2019 Nov 14, 2019	SELL	$9.41 - $16.56 $236,294 - $415,838	-25,111 Reduced 55.4%	20,216 $241,000
Q2 2019 Aug 14, 2019	BUY	$8.98 - $12.96 $119,730 - $172,795	13,333 Added 41.67%	45,327 $548,000
Q1 2019 May 15, 2019	BUY	$6.5 - $13.77 $206,466 - $437,390	31,764 Added 13810.43%	31,994 $401,000
Q4 2018 Feb 14, 2019	SELL	$6.3 - $10.44 $1.27 Million - $2.11 Million	-201,980 Reduced 99.89%	230 $1,000
Q3 2018 Nov 14, 2018	SELL	$6.82 - $11.26 $627,303 - $1.04 Million	-91,980 Reduced 31.27%	202,210 $2.08 Million
Q2 2018 Aug 14, 2018	BUY	$5.99 - $9.1 $1.67 Million - $2.54 Million	279,174 Added 1859.18%	294,190 $1.98 Million
Q1 2018 Oct 18, 2019	BUY	$8.46 - $23.08 $21,259 - $58,000	2,513 Added 20.1%	15,016 $128,000
Q1 2018 May 15, 2018	SELL	$8.46 - $23.08 $114,912 - $313,495	-13,583 Reduced 52.07%	12,503 $106,000
Q4 2017 Feb 14, 2018	BUY	$14.47 - $20.8 $252,009 - $362,252	17,416 Added 200.88%	26,086 $541,000
Q3 2017 Nov 14, 2017	BUY	$10.61 - $17.98 $91,988 - $155,886	8,670	8,670 $152,000

Others Institutions Holding PTGX

# of Institutions

246

Shares Held

56.4M

Call Options Held

76.3K

Put Options Held

114K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $2.02B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account